Significant Ownership of Sarepta Therapeutics, Inc.

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for Sarepta Therapeutics, Inc. focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
/s/ Ryan Wong - Ryan Wong, Executive Vice President, Chief Financial Officer
Manager location
Cambridge, MA

Follow Filing Activity

Follow Sarepta Therapeutics, Inc. with Pro and return when a new Schedule 13D/G filing changes the record on this page.

Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.

Review Pro alert access Already have an account? Sign in and return here

Significant Ownership of Sarepta Therapeutics, Inc.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARWR ARROWHEAD PHARMACEUTICALS, INC. Common stock, par value $0.001 per share (the "Common Stock") 0% $0 -$200,242,594 0 -100% Sarepta Therapeutics, Inc. 13 Aug 2025

Schedules 13D/G Reported by Sarepta Therapeutics, Inc.:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .